tiprankstipranks
Trending News
More News >
Viridian Therapeutics (VRDN)
NASDAQ:VRDN
US Market

Viridian Therapeutics (VRDN) Stock Forecast & Price Target

Compare
1,373 Followers
See the Price Targets and Ratings of:

VRDN Analyst Ratings

Strong Buy
12Ratings
Strong Buy
10 Buy
2 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Viridian
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

VRDN Stock 12 Month Forecast

Average Price Target

$38.80
▲(164.31%Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Viridian Therapeutics in the last 3 months. The average price target is $38.80 with a high forecast of $61.00 and a low forecast of $19.00. The average price target represents a 164.31% change from the last price of $14.68.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","23":"$23","36":"$36","49":"$49","62":"$62"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":61,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$61.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$38.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$19.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,23,36,49,62],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.74,17.375384615384615,21.01076923076923,24.646153846153844,28.28153846153846,31.916923076923077,35.55230769230769,39.18769230769231,42.823076923076925,46.45846153846154,50.09384615384616,53.729230769230774,57.364615384615384,{"y":61,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.74,15.667692307692308,17.595384615384614,19.52307692307692,21.45076923076923,23.378461538461536,25.306153846153844,27.23384615384615,29.16153846153846,31.089230769230767,33.01692307692307,34.94461538461538,36.872307692307686,{"y":38.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.74,14.144615384615385,14.54923076923077,14.953846153846154,15.358461538461539,15.763076923076923,16.167692307692306,16.572307692307692,16.97692307692308,17.38153846153846,17.786153846153844,18.19076923076923,18.595384615384617,{"y":19,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.81,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.95,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.21,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.28,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.68,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.61,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.28,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.17,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.38,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.53,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.56,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$61.00Average Price Target$38.80Lowest Price Target$19.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on VRDN
TipRanks AITipRanks
Not Ranked
TipRanks
$13.5
Hold
-8.04%
Downside
Upgraded
05/22/25
Viridian Therapeutics' overall stock score is influenced primarily by its significant financial challenges and a cautious technical outlook. However, the positive phase 3 trial results and strategic board appointment provide some optimism for future growth, balancing the financial difficulties.
Stifel Nicolaus Analyst forecast on VRDN
Alex Thompson CFAStifel Nicolaus
Stifel Nicolaus
$12.82$41
Buy
179.29%
Upside
Reiterated
05/26/25
Analysts Offer Insights on Healthcare Companies: Vigil Neuroscience Inc (NASDAQ: VIGL), Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF) and Viridian Therapeutics (NASDAQ: VRDN)
B.Riley Financial Analyst forecast on VRDN
Kalpit PatelB.Riley Financial
B.Riley Financial
$19
Hold
29.43%
Upside
Reiterated
05/21/25
B.Riley reiterates Neutral Rating on Viridian Therapeutic (VRDN)B.Riley analyst Kalpit Patel reiterated a Neutral rating and $19.00 price target on Viridian Therapeutic (NASDAQ: VRDN).
Leerink Partners Analyst forecast on VRDN
Thomas SmithLeerink Partners
Leerink Partners
Buy
Reiterated
05/20/25
Viridian Therapeutics' Veligrotug Shows Promising Durability and Safety in TED Treatment, Justifying Buy Rating
LifeSci Capital Analyst forecast on VRDN
Rami KatkhudaLifeSci Capital
LifeSci Capital
$46
Buy
213.35%
Upside
Reiterated
05/20/25
Viridian Therapeutics: Buy Rating Affirmed on Promising Phase III Results and Strategic Growth Plans
H.C. Wainwright Analyst forecast on VRDN
Douglas TsaoH.C. Wainwright
H.C. Wainwright
$34
Buy
131.61%
Upside
Reiterated
05/20/25
Viridian Therapeutics: Promising Data and Market Position Justify Buy Rating
BTIG
$61
Buy
315.53%
Upside
Reiterated
05/20/25
Viridian Therapeutics: Promising Developments in Thyroid Eye Disease Treatment Drive Buy Rating
Wedbush
$41
Buy
179.29%
Upside
Reiterated
05/20/25
Promising Long-Term Data and Strategic Advancements Position Viridian Therapeutics for Growth
Needham
$36
Buy
145.23%
Upside
Reiterated
05/20/25
Positive Outlook for Viridian Therapeutics: Buy Rating Affirmed on Promising Trial Results and Future Prospects
TD Cowen Analyst forecast on VRDN
Joseph ThomeTD Cowen
TD Cowen
Buy
Reiterated
05/20/25
TD Cowen Sticks to Their Buy Rating for Viridian Therapeutics (VRDN)
Citizens JMP Analyst forecast on VRDN
Jason ButlerCitizens JMP
Citizens JMP
$42$38
Buy
158.86%
Upside
Reiterated
05/07/25
Viridian Therapeutics price target lowered to $38 from $42 at Citizens JMPViridian Therapeutics price target lowered to $38 from $42 at Citizens JMP
RBC Capital Analyst forecast on VRDN
Gregory RenzaRBC Capital
RBC Capital
$46$45
Buy
206.54%
Upside
Reiterated
05/06/25
Viridian Therapeutics (VRDN) Receives a Buy from RBC Capital
Wells Fargo Analyst forecast on VRDN
Derek ArchilaWells Fargo
Wells Fargo
$27
Hold
83.92%
Upside
Reiterated
05/06/25
Viridian Therapeutics: Hold Rating Amid Limited Near-Term Catalysts and Awaited 2026 Data
Oppenheimer Analyst forecast on VRDN
Leland GershellOppenheimer
Oppenheimer
$28
Buy
90.74%
Upside
Reiterated
12/17/24
Viridian Therapeutics (VRDN) Gets a Buy from Oppenheimer
Evercore ISI Analyst forecast on VRDN
Unknown AnalystEvercore ISI
Not Ranked
Evercore ISI
$41
Buy
179.29%
Upside
Assigned
12/17/24
We wish mgmt. showed the proptosis/diplopia data specifically in the baseline CAS0/1 subgroup to definitively address this point, but did note on the call that benefit on both measures was independent of CAS response – which is a clear positive. Even if some investors remain skeptical and want to see this full data, the point remains that VRDN clearly has this as an (on label) marketing advantage over Tepezza (in addition to infusion time, # cycles). Point #2) safety, mainly hearing events, is solid and largely in line with THRIVE We continue to focus most on hearing impairments, since that has the most readthrough to long T1/2 subQ 003. Pbo came
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on VRDN
TipRanks AITipRanks
Not Ranked
TipRanks
$13.5
Hold
-8.04%
Downside
Upgraded
05/22/25
Viridian Therapeutics' overall stock score is influenced primarily by its significant financial challenges and a cautious technical outlook. However, the positive phase 3 trial results and strategic board appointment provide some optimism for future growth, balancing the financial difficulties.
Stifel Nicolaus Analyst forecast on VRDN
Alex Thompson CFAStifel Nicolaus
Stifel Nicolaus
$12.82$41
Buy
179.29%
Upside
Reiterated
05/26/25
Analysts Offer Insights on Healthcare Companies: Vigil Neuroscience Inc (NASDAQ: VIGL), Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF) and Viridian Therapeutics (NASDAQ: VRDN)
B.Riley Financial Analyst forecast on VRDN
Kalpit PatelB.Riley Financial
B.Riley Financial
$19
Hold
29.43%
Upside
Reiterated
05/21/25
B.Riley reiterates Neutral Rating on Viridian Therapeutic (VRDN)B.Riley analyst Kalpit Patel reiterated a Neutral rating and $19.00 price target on Viridian Therapeutic (NASDAQ: VRDN).
Leerink Partners Analyst forecast on VRDN
Thomas SmithLeerink Partners
Leerink Partners
Buy
Reiterated
05/20/25
Viridian Therapeutics' Veligrotug Shows Promising Durability and Safety in TED Treatment, Justifying Buy Rating
LifeSci Capital Analyst forecast on VRDN
Rami KatkhudaLifeSci Capital
LifeSci Capital
$46
Buy
213.35%
Upside
Reiterated
05/20/25
Viridian Therapeutics: Buy Rating Affirmed on Promising Phase III Results and Strategic Growth Plans
H.C. Wainwright Analyst forecast on VRDN
Douglas TsaoH.C. Wainwright
H.C. Wainwright
$34
Buy
131.61%
Upside
Reiterated
05/20/25
Viridian Therapeutics: Promising Data and Market Position Justify Buy Rating
BTIG
$61
Buy
315.53%
Upside
Reiterated
05/20/25
Viridian Therapeutics: Promising Developments in Thyroid Eye Disease Treatment Drive Buy Rating
Wedbush
$41
Buy
179.29%
Upside
Reiterated
05/20/25
Promising Long-Term Data and Strategic Advancements Position Viridian Therapeutics for Growth
Needham
$36
Buy
145.23%
Upside
Reiterated
05/20/25
Positive Outlook for Viridian Therapeutics: Buy Rating Affirmed on Promising Trial Results and Future Prospects
TD Cowen Analyst forecast on VRDN
Joseph ThomeTD Cowen
TD Cowen
Buy
Reiterated
05/20/25
TD Cowen Sticks to Their Buy Rating for Viridian Therapeutics (VRDN)
Citizens JMP Analyst forecast on VRDN
Jason ButlerCitizens JMP
Citizens JMP
$42$38
Buy
158.86%
Upside
Reiterated
05/07/25
Viridian Therapeutics price target lowered to $38 from $42 at Citizens JMPViridian Therapeutics price target lowered to $38 from $42 at Citizens JMP
RBC Capital Analyst forecast on VRDN
Gregory RenzaRBC Capital
RBC Capital
$46$45
Buy
206.54%
Upside
Reiterated
05/06/25
Viridian Therapeutics (VRDN) Receives a Buy from RBC Capital
Wells Fargo Analyst forecast on VRDN
Derek ArchilaWells Fargo
Wells Fargo
$27
Hold
83.92%
Upside
Reiterated
05/06/25
Viridian Therapeutics: Hold Rating Amid Limited Near-Term Catalysts and Awaited 2026 Data
Oppenheimer Analyst forecast on VRDN
Leland GershellOppenheimer
Oppenheimer
$28
Buy
90.74%
Upside
Reiterated
12/17/24
Viridian Therapeutics (VRDN) Gets a Buy from Oppenheimer
Evercore ISI Analyst forecast on VRDN
Unknown AnalystEvercore ISI
Not Ranked
Evercore ISI
$41
Buy
179.29%
Upside
Assigned
12/17/24
We wish mgmt. showed the proptosis/diplopia data specifically in the baseline CAS0/1 subgroup to definitively address this point, but did note on the call that benefit on both measures was independent of CAS response – which is a clear positive. Even if some investors remain skeptical and want to see this full data, the point remains that VRDN clearly has this as an (on label) marketing advantage over Tepezza (in addition to infusion time, # cycles). Point #2) safety, mainly hearing events, is solid and largely in line with THRIVE We continue to focus most on hearing impairments, since that has the most readthrough to long T1/2 subQ 003. Pbo came
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Viridian Therapeutics

1 Month
xxx
Success Rate
11/24 ratings generated profit
46%
Average Return
+1.78%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 45.83% of your transactions generating a profit, with an average return of +1.78% per trade.
3 Months
xxx
Success Rate
13/24 ratings generated profit
54%
Average Return
+2.21%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 54.17% of your transactions generating a profit, with an average return of +2.21% per trade.
1 Year
Success Rate
17/40 ratings generated profit
43%
Average Return
-4.17%
reiterated a buy rating 20 days ago
Copying Laura Chico's trades and holding each position for 1 Year would result in 42.50% of your transactions generating a profit, with an average return of -4.17% per trade.
2 Years
xxx
Success Rate
9/26 ratings generated profit
35%
Average Return
+7.83%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 34.62% of your transactions generating a profit, with an average return of +7.83% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VRDN Analyst Recommendation Trends

Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
30
25
14
11
16
Buy
5
6
5
3
4
Hold
1
2
1
1
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
36
33
20
15
23
In the current month, VRDN has received 20 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. VRDN average Analyst price target in the past 3 months is 38.80.
Each month's total comprises the sum of three months' worth of ratings.

VRDN Financial Forecast

VRDN Earnings Forecast

Next quarter’s earnings estimate for VRDN is -$1.01 with a range of -$1.17 to -$0.81. The previous quarter’s EPS was -$0.87. VRDN beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year VRDN has Outperformed its overall industry.
Next quarter’s earnings estimate for VRDN is -$1.01 with a range of -$1.17 to -$0.81. The previous quarter’s EPS was -$0.87. VRDN beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year VRDN has Outperformed its overall industry.

VRDN Sales Forecast

Next quarter’s sales forecast for VRDN is $51.00K with a range of $0.00 to $250.00K. The previous quarter’s sales results were $72.00K. VRDN beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.56% of the time in the same period. In the last calendar year VRDN has Outperformed its overall industry.
Next quarter’s sales forecast for VRDN is $51.00K with a range of $0.00 to $250.00K. The previous quarter’s sales results were $72.00K. VRDN beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.56% of the time in the same period. In the last calendar year VRDN has Outperformed its overall industry.

VRDN Stock Forecast FAQ

What is VRDN’s average 12-month price target, according to analysts?
Based on analyst ratings, Viridian Therapeutics’s 12-month average price target is 38.80.
    What is VRDN’s upside potential, based on the analysts’ average price target?
    Viridian Therapeutics has 164.31% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is VRDN a Buy, Sell or Hold?
          Viridian Therapeutics has a consensus rating of Strong Buy which is based on 10 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Viridian Therapeutics’s price target?
            The average price target for Viridian Therapeutics is 38.80. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $61.00 ,the lowest forecast is $19.00. The average price target represents 164.31% Increase from the current price of $14.68.
              What do analysts say about Viridian Therapeutics?
              Viridian Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of VRDN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis